4/15
04:01 pm
wve
Wave Life Sciences Announces Proposed Redomiciliation to the United States
Medium
Report
Wave Life Sciences Announces Proposed Redomiciliation to the United States
4/14
07:13 am
wve
WAVE Life Sciences (WVE) had its "buy" rating reaffirmed by HC Wainwright.
Low
Report
WAVE Life Sciences (WVE) had its "buy" rating reaffirmed by HC Wainwright.
4/12
01:00 am
wve
Low
Report
4/1
05:15 pm
wve
Is This Weight Loss Drug Stock a Buy on the Dip? [Yahoo! Finance]
Medium
Report
Is This Weight Loss Drug Stock a Buy on the Dip? [Yahoo! Finance]
3/31
02:45 am
wve
Wave Life Sciences Obesity Data Highlights Visceral Fat Focus Over Weight Loss [Yahoo! Finance]
Medium
Report
Wave Life Sciences Obesity Data Highlights Visceral Fat Focus Over Weight Loss [Yahoo! Finance]
3/30
07:57 am
wve
Wave Life Sciences Ltd. (WVE) PT Increased to $52 at Canaccord Following Pipeline Review [Yahoo! Finance]
Medium
Report
Wave Life Sciences Ltd. (WVE) PT Increased to $52 at Canaccord Following Pipeline Review [Yahoo! Finance]
3/27
08:05 pm
wve
Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip? [Yahoo! Finance]
Medium
Report
Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip? [Yahoo! Finance]
3/27
01:25 pm
wve
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks [Yahoo! Finance]
Medium
Report
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks [Yahoo! Finance]
3/27
10:23 am
wve
Wave Life Sciences Slips as Obesity Data Fails to Convince [Yahoo! Finance]
Low
Report
Wave Life Sciences Slips as Obesity Data Fails to Convince [Yahoo! Finance]
3/27
10:22 am
wve
WAVE Life Sciences (WVE) had its price target lowered by Bank of America Corporation from $38.00 to $21.00. They now have a "buy" rating on the stock.
Low
Report
WAVE Life Sciences (WVE) had its price target lowered by Bank of America Corporation from $38.00 to $21.00. They now have a "buy" rating on the stock.
3/27
08:58 am
wve
WAVE Life Sciences (WVE) had its price target lowered by Wells Fargo & Company from $27.00 to $13.00. They now have an "overweight" rating on the stock.
Medium
Report
WAVE Life Sciences (WVE) had its price target lowered by Wells Fargo & Company from $27.00 to $13.00. They now have an "overweight" rating on the stock.
3/27
06:17 am
wve
Wave crashes on obesity drug update; Kodiak's reboot pays dividends [Yahoo! Finance]
Low
Report
Wave crashes on obesity drug update; Kodiak's reboot pays dividends [Yahoo! Finance]
3/26
07:41 pm
wve
WAVE Life Sciences Shares Phase 1 WVE-007 Data Showing Visceral Fat Loss, Muscle Preservation Signal [Yahoo! Finance]
Low
Report
WAVE Life Sciences Shares Phase 1 WVE-007 Data Showing Visceral Fat Loss, Muscle Preservation Signal [Yahoo! Finance]
3/26
05:56 pm
wve
Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints [Yahoo! Finance]
Medium
Report
Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints [Yahoo! Finance]
3/26
04:38 pm
wve
Wave Life Sciences: WVE-007 Data Leaves Biotech Shaken And Stirred (Downgrade) [Seeking Alpha]
Medium
Report
Wave Life Sciences: WVE-007 Data Leaves Biotech Shaken And Stirred (Downgrade) [Seeking Alpha]
3/25
10:29 am
wve
WAVE Life Sciences (WVE) had its price target raised by Mizuho from $22.00 to $27.00. They now have an "outperform" rating on the stock.
Low
Report
WAVE Life Sciences (WVE) had its price target raised by Mizuho from $22.00 to $27.00. They now have an "outperform" rating on the stock.
3/10
12:34 pm
wve
WAVE Life Sciences (WVE) had its price target raised by Canaccord Genuity Group Inc. from $43.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
WAVE Life Sciences (WVE) had its price target raised by Canaccord Genuity Group Inc. from $43.00 to $52.00. They now have a "buy" rating on the stock.
3/6
09:17 am
wve
WAVE Life Sciences (WVE) had its price target raised by Wedbush from $33.00 to $35.00. They now have an "outperform" rating on the stock.
Low
Report
WAVE Life Sciences (WVE) had its price target raised by Wedbush from $33.00 to $35.00. They now have an "outperform" rating on the stock.
3/5
09:01 am
wve
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference [Yahoo! Finance]
Medium
Report
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference [Yahoo! Finance]
3/5
08:30 am
wve
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
Low
Report
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
3/2
08:03 am
wve
WAVE Life Sciences (WVE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
WAVE Life Sciences (WVE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.
3/2
07:19 am
wve
Wave Life Sciences Teases Near-Term Obesity and RNA Editing Data as INLIGHT Readouts Near [Yahoo! Finance]
Low
Report
Wave Life Sciences Teases Near-Term Obesity and RNA Editing Data as INLIGHT Readouts Near [Yahoo! Finance]
2/28
01:40 pm
wve
Wave Life Sciences Ltd. (WVE): A Bull Case Theory [Yahoo! Finance]
Low
Report
Wave Life Sciences Ltd. (WVE): A Bull Case Theory [Yahoo! Finance]
2/28
04:59 am
wve
Wave Life Sciences Ltd. (WVE) Announces Fiscal Q4 and Full-Year 2025 Earnings [Yahoo! Finance]
Low
Report
Wave Life Sciences Ltd. (WVE) Announces Fiscal Q4 and Full-Year 2025 Earnings [Yahoo! Finance]
2/26
08:13 am
wve
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]